Table 2.
Primary and secondary endpoints at 12 weeks after treatment initiation
| Continuous secondary endpoints | Dapagliflozin (n = 162) | Placebo (n = 162) | Effect size | P value |
|---|---|---|---|---|
| KCCQ-CS, meana | 68.6 (66.2, 71.0) | 62.8 (60.4, 65.3) | 5.8 (2.3, 9.2) | 0.001 |
| KCCQ-OS, meana | 68.9 (66.5, 71.3) | 64.5 (62.1, 66.8) | 4.5 (1.1, 7.8) | 0.009 |
| 6MWT, mean, ma | 262 (252, 272) | 242 (232, 252) | 20.1 (5.6, 34.7) | 0.007 |
| NTproBNP, mean, pg ml–1a | 733 (673, 799) | 739 (678, 805) | 0.99 (0.88, 1.12)b | 0.900 |
| BNP, mean, pg ml–1a | 147 (136, 160) | 147 (136, 160) | 1.00 (0.89, 1.12)b | 0.990 |
| Systolic blood pressure, mean, mmHga | 133 (130, 135) | 133 (131, 136) | −0.6 (−4.4, 3.3) | 0.780 |
| Weight, mean, kga | 101.3 (100.9, 101.8) | 102.1 (101.6, 102.6) | −0.72 (−1.42, −0.01) | 0.046 |
Values are shown as adjusted means (95% CI) for continuous variables.
aAdjusted for the corresponding baseline value, history of T2D, sex, AF, baseline eGFR and LVEF.
bRatio of dapagliflozin compared to placebo.